Skip to content
Article Rich – Lifestyle
Author:
Deerfield Group
DEERFIELD GROUP ANNOUNCES STRATEGIC INVESTMENT FROM MARTIS CAPITAL TO FUEL NEXT PHASE OF GROWTH
June 30, 2026
Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
/C O R R E C T I O N — InMed Pharmaceuticals/
May 22, 2026
Petrichor Names Diagnostics Industry Leader Don Hardison as Operating Partner
May 22, 2026
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
May 22, 2026
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
May 21, 2026
HERVolution Therapeutics Appoints Dr. László B. Tankó to Scientific Advisory Board to Strengthen Cardiometabolic Clinical Development Strategy
April 28, 2026
Deerfield Group Launches Prismatiq™, an Intuitive Field Enablement Platform Purpose-Built for Life Sciences
April 22, 2026
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
April 17, 2026
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
April 17, 2026
1
2
Next Page
→